Buy Novocainamide pills 0.25 g pills 250 mg, 20 pcs
  • Buy Novocainamide pills 0.25 g pills 250 mg, 20 pcs


1427 Items
Dosage form
Brand & Manufacturer
Package Size
  • done All payments are SSL encrypted
  • done Full Refund if you haven't received your order
  • done International shipping to the USA, UK and Europe

Clinical Pharmacology

Novocainamide has a membrane stabilizing effect.

Reduces the excitability and conductivity of the heart muscle, inhibits the formation of impulses in the foci of automatism, has a local anesthetic effect.


Applied with various violations of the heart rhythm:
Ventricular arrhythmias.
Paroxysmal ventricular tachycardia.
Supraventricular arrhythmias.
Paroxysmal atrial fibrillation or atrial flutter.


Novocainamide 0.25 g (250 mg).

No customer reviews for the moment.

Write your review

Write your review


Dosage and Administration

IM - 5–10 ml of 1–2% solution 3 times a week for a month, after which a 10-day break is taken.

For infiltration anesthesia, 0.25–0.5% solutions are used, for conductive and epidural - 2% solution; inside - 1/2 tsp (with pain).

Adverse reactions

From the central and peripheral nervous system: headache, dizziness, drowsiness, weakness, motor restlessness, loss of consciousness, convulsions, trismus, tremor, visual and auditory disturbances, nystagmus, horse tail syndrome (paralysis of the legs, paresthesia), paralysis of the respiratory muscles, impaired sensory and motor conduction, paralysis respiratory center often develops with subarachnoid anesthesia.


  • hypersensitivity (including to para-aminobenzoic acid and other local anesthetics, esters),
  • children's age (up to 18 years).


Drug interactions

Local anesthetics increase the inhibitory effect on the central nervous system of other drugs. Anticoagulants (ardeparin sodium, dalteparin sodium, danaparoid sodium, enoxaparin sodium, heparin, warfarin) increase the risk of bleeding.

Pregnancy and Lactation

During periods of pregnancy and breastfeeding, the drug should be used when the benefit to the mother exceeds the risk to the fetus or child.

Special instructions

During the period of treatment, care must be taken when driving vehicles and engaging in other potentially hazardous activities that require increased concentration and psychomotor speed.


Symptoms: pallor of the skin and mucous membranes, dizziness, nausea, vomiting, increased nervous irritability, cold sweat, tachycardia, decrease in blood pressure to almost collapse, tremor, convulsions, apnea, methemoglobinemia, respiratory depression, sudden cardiovascular, respiratory depression, sudden hemorrhage, apnea, methemoglobinemia, respiratory depression, sudden cardio-vascular

The effect on the central nervous system is manifested by a sense of fear, hallucinations, convulsions, motor agitation. In cases of overdose, the administration of the drug should be immediately stopped. When conducting local anesthesia, the site of injection can be tipped with adrenaline.

Treatment: general resuscitation measures that include inhalation of oxygen, if necessary, carrying out artificial ventilation of the lungs.

If convulsions continue for more than 15–20 sec, they are stopped by intravenous administration of thiopental (100–150 mg) or diazepam (5–20 mg).

In case of arterial hypotension and / or depression of the myocardium, ephedrine (15-30 mg) is injected intravenously, in severe cases, detoxification and symptomatic therapy.

In the event of intoxication after injection of novocaine into the muscles of the leg or arm, an urgent imposition of the harness is recommended to reduce the subsequent flow of the drug into the bloodstream.

  • Brand name: Novocainamide pills 0.25 g
  • Active ingredient: Procainamide
  • Dosage form: Pills.
  • Manufacturer: Organics
  • Country of Origin: Russia

Studies and clinical trials of Procainamide (Click to expand)

  1. The influence of moderate and chronic exercise training on the pharmacokinetics of procainamide and N-acetylprocainamide
  2. Unusual case of antiphospholipid antibody syndrome presenting with extensive cutaneous infarcts in a patient on long-term procainamide therapy
  3. Circulating inhibitors of blood coagulation associated with procainamide-induced lupus erythematosus
  4. Procainamide-induced thrombocytopenia
  5. Procainamide-induced agranulocytosis with reversible myeloid sensitivity
  6. Procainamide-associated pancytopenia
  7. Another case of procainamide induced pancytopenia
  8. Polyradiculoneuropathy accompaning procainamide-induced lupus erythematosus: Evidence for drug-induced enhanced sensitization to peripheral nerve myelin
  9. Cyclovinylogues of Procainamide
  10. Procainamide-induced serologic changes in asymptomatic patients
  11. Development of antibodies to ribonucleoprotein following short-term therapy with procainamide
  12. Cryoglobulins in the procainamide-induced lupus syndrome
  13. The implications of procainamide metabolism to its induction of lupus
  14. Procainamide-lymphocyte reactions. a possible explanation for drug-induced autoimmunity
  15. Antigen-specific suppressor cell activity in procainamide therapy
  16. Effects of long-term procainamide therapy on immunoglobulin synthesis
  17. Autoantigenic histone epitopes: a comparison between procainamide- and hydralazine-induced lupus
  18. N-acetylprocainamide is a less potent inducer of t cell autoreactivity than procainamide
  19. Serologic Evaluation of Patients Receiving Procainamide
  20. Mechanisms of drug-induced lupus. IV. Comparison of procainamide and hydralazine with analogs in vitro and in vivo
  21. Concentration-dependent clearance of procainamide in normal subjects
  22. Liquid chromatographic analysis of mexiletine in serum, with alternate application to tocainide, procainamide, and N-acetylprocainamide
  23. Synthesis of 4-[N- [2-(Methacryloyloxy) Ethoxycarbonyl) ]Amino-N′-[2- (Diethylamino) Ethyl]Benzamide; A Novel Polymerizable Derivative of Procainamide
  24. Synthesis of Some Low Molecular Weight Derivatives of Procainamide

8 other products in the same category: